COVID-19-neutralizing antibodies predict disease severity and survival.
COVID-19-neutralizing antibodies predict disease severity and survival.
复制标题
DOI：
10.1016/j.cell.2020.12.015
复制
发表时间：
2021-01-21
期刊：
影响因子：
64.5
通讯作者：
Balazs AB
中科院分区：
文献类型：
--
作者：
Garcia-Beltran WF;Lam EC;Astudillo MG;Yang D;Miller TE;Feldman J;Hauser BM;Caradonna TM;Clayton KL;Nitido AD;Murali MR;Alter G;Charles RC;Dighe A;Branda JA;Lennerz JK;Lingwood D;Schmidt AG;Iafrate AJ;Balazs AB
冠状病毒病2019(新冠肺炎)表现出从无症状到危及生命的不同症状严重性，但严重性与体液免疫反应之间的关系尚不清楚。我们检测了113名新冠肺炎患者的抗体反应，发现导致插管或死亡的重症患者表现出炎症标志物、淋巴细胞减少、促炎细胞因子和高水平的抗受体结合结构域(RBD)抗体水平。虽然抗RBD免疫球蛋白G(Ig G)水平通常与中和效价相关，但中和效价的定量显示高效价是生存的预测因素。除了对野生型SARS-CoV-2的中和外，患者血清还能够中和最近出现的SARS-CoV-2突变株D614G，这表明对任何一种毒株的再次感染都具有交叉保护作用。然而，SARS-CoV-2血清通常缺乏与高度同源的前紧急蝙蝠冠状病毒WIV1-CoV的交叉中和，而WIV1-CoV尚未跨越物种屏障。这些结果突显了中和体液免疫对疾病进展的重要性，以及需要制定广泛的保护性干预措施，以防止未来的冠状病毒大流行。严重的新冠肺炎与更高的抗体产生和中和滴度相关抗RBD抗体的中和效力预测疾病的严重程度和生存新冠肺炎指导的免疫调节疗法调节抗体反应新冠肺炎血清中和D614和G614变异，但不能中和发病前的WIV1冠状病毒Garcia-Beltran等人。研究表明，在感染SARS-CoV-2期间产生更强大的中和抗体可以预测新冠肺炎的存活率。保护性抗体反应对目前流行的SARS-CoV-2 D614G尖峰变异具有很强的中和作用，但对新出现的WIV1-CoV尖峰缺乏显著活性，这表明恢复期患者可能仍然容易受到未来大流行的影响。
Coronavirus disease 2019 (COVID-19) exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-receptor binding domain (RBD) antibody levels. Although anti-RBD immunoglobulin G (IgG) levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting cross-protection from reinfection by either strain. However, SARS-CoV-2 sera generally lacked cross-neutralization to a highly homologous pre-emergent bat coronavirus, WIV1-CoV, which has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics. Severe COVID-19 associates with higher antibody production and neutralization titers Neutralization potency of anti-RBD antibodies predicts disease severity and survival Immunomodulatory COVID-19-directed therapies modulate antibody responses COVID-19 sera neutralize D614 and G614 variants, but not pre-emergent WIV1-CoV Garcia-Beltran et al. show that the development of more potent neutralizing antibodies during SARS-CoV-2 infection predicts COVID-19 survival. Protective antibody responses exhibit potent neutralization against the currently circulating SARS-CoV-2 D614G spike variant but lack significant activity against pre-emergent WIV1-CoV spike, suggesting that convalescent patients are likely to remain susceptible to future pandemics.
登录
查看更多内容
影响因子：
25.4
作者：
Guaraldi, Giovanni;Meschiari, Marianna;Mussini, Cristina
通讯作者：
Mussini, Cristina
DOI：
10.1126/science.abe8499
发表时间：
2020-12-18
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Hou YJ;Chiba S;Halfmann P;Ehre C;Kuroda M;Dinnon KH 3rd;Leist SR;Schäfer A;Nakajima N;Takahashi K;Lee RE;Mascenik TM;Graham R;Edwards CE;Tse LV;Okuda K;Markmann AJ;Bartelt L;de Silva A;Margolis DM;Boucher RC;Randell SH;Suzuki T;Gralinski LE;Kawaoka Y;Baric RS
通讯作者：
Baric RS
影响因子：
5
作者：
Hannoun, C;Megas, F;Piercy, J
通讯作者：
Piercy, J
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
158.5
作者：
Boulware, David R.;Pullen, Matthew F.;Hullsiek, Kathy H.
通讯作者：
Hullsiek, Kathy H.